Megan Ingram
Subscribe to Megan Ingram's PostsMegan Ingram focuses her practice on assessing and mitigating antitrust risk in public and private M&A transactions. She supports US and international clients with merger review, obtaining clearance under the Hart-Scott-Rodino Act, antitrust compliance, and governmental antitrust investigations. Megan has experience across multiple industries, including software and technology, healthcare and life sciences, consumer products, aerospace and defense, and industrials. Read Megan Ingram's full bio.
Heard at the 2025 Antitrust Law Section Spring Meeting
By Lisa P. Rumin, Reese Poncia, Anthony S. Ferrara, Elai Katz, Megan Ingram, Royce Brosseau, Claire Danberg, Betty Zhang and Alex Grayson on Apr 10, 2025
Posted In Cartel Enforcement, Consumer Protection/Privacy, DOJ Developments, EC Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
The American Bar Association Antitrust Law Section held its annual Spring Meeting from April 2 to 5 in Washington, DC, where federal, state, and international antitrust enforcers shared key updates and enforcement priorities. At the Spring Meeting, antitrust agencies signaled continued scrutiny of mergers, noncompete agreements, and Big Tech – plus an uptick in state-level...
Continue Reading
Antitrust Under Trump: March 2025 Updates
By Jon B. Dubrow, Michelle Lowery and Megan Ingram on Apr 1, 2025
Posted In DOJ Developments, FTC Developments
The Trump administration has taken significant steps to reshape antitrust enforcement by exerting greater control over the Federal Trade Commission (FTC), firing two Democratic FTC commissioners. Leadership has also begun to outline more of their priorities in speeches and interviews. These changes outline antitrust enforcement priorities, with a stronger emphasis on economic analysis and litigation...
Continue Reading
Antitrust Under Trump: Initial Policies and Actions
By Jon B. Dubrow, Michelle Lowery and Megan Ingram on Mar 6, 2025
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Joint Ventures/Competitor Collaboration, Mergers & Acquisitions, Monopolization/Abuse of Dominance
The Trump administration has initiated significant changes in antitrust policy through key appointments and policy announcements. The administration announced that the Federal Trade Commission (FTC) and US Department of Justice (DOJ) will continue using the 2023 Merger Guidelines and expressed support for new Hart-Scott-Rodino (HSR) rules. Additionally, the FTC outlined its goals, which include improving...
Continue Reading
